US Salivary Gland Infection Market Summary
The US Salivary Gland Infection market is projected to grow from 1.5 USD billion in 2024 to 4 USD billion by 2035.
Key Market Trends & Highlights
US Salivary Gland Infection Key Trends and Highlights
- The market is expected to experience a compound annual growth rate (CAGR) of 9.33 percent from 2025 to 2035.
- By 2035, the market valuation is anticipated to reach 4 USD billion, indicating robust growth potential.
- In 2024, the market is valued at 1.5 USD billion, reflecting the current demand for treatment options.
- Growing adoption of advanced diagnostic techniques due to increasing awareness of salivary gland infections is a major market driver.
Market Size & Forecast
2024 Market Size | 1.5 (USD Billion) |
2035 Market Size | 4 (USD Billion) |
CAGR (2025-2035) | 9.33% |
Major Players
Merck and Co, Teva Pharmaceutical Industries, AstraZeneca, Novartis, Eli Lilly, GlaxoSmithKline, Bristol Myers Squibb, Gilead Sciences, Pfizer, Amgen, Roche, AbbVie, Sanofi, Johnson and Johnson, Bayer